NCT03610906
Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
Enrolling by Invitation
Not specifiedAges 30–21ObservationalUniversity of Colorado, DenverInvestigator-initiated
~250 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Tumor and Blood Specimens
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identification of Potential Therapeutic Targets
Measured over Beginning of study to end of study, up to 1 year.
+4 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesColorado1
Study leadership
- Todd Hankinson, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through mRNA expression.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through microarray analysis.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets immunohistochemistry.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through quantitative PCR.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will also perform immunostaining for beta-catenin and use DNA SNaPshot analysis to determine what parts of the tumor are responsible for observed gene signatures.